Screener
Lexicon Pharmaceuticals LXRX Gain (loss) on extinguishment of debt
Gain (loss) on extinguishment of debt at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| (Loss) income from operations | (26,540) | 3,736 | (27,536) | (21,943) |
| Interest and other expense | (2,609) | (2,318) | (4,199) | (4,153) |
| Interest and other income | 1,723 | 1,834 | 3,266 | 4,053 |
| Loss on early extinguishment of debt | (4,349) | — | (4,349) | — |
| Net (loss) income | $(31,775) | $3,252 | $(32,818) | $(22,043) |
| Net (loss) income per common share, basic | $(0.07) | $0.01 | $(0.08) | $(0.06) |
| Net (loss) income per common share, diluted | $(0.07) | $0.01 | $(0.08) | $(0.06) |
| Weighted average common shares outstanding, basic | 437,653 | 363,294 | 419,050 | 362,687 |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's gain (loss) on extinguishment of debt?
- Lexicon Pharmaceuticals (LXRX) reported gain (loss) on extinguishment of debt of -$4.35M in Q2 2026.
- What does gain (loss) on extinguishment of debt mean?
- Gains or losses from retiring debt before maturity — gains when debt is repurchased below par, losses when premiums are paid for early redemption.
Ask your AI about Lexicon Pharmaceuticals's gain (loss) on extinguishment of debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude